Immunohistochemistry, CD 79A Hyderabad | Focus Diagnostics

The IHC – CD79a (Cluster of Differentiation 79A) test is an immunohistochemistry-based diagnostic test used to detect CD79a protein expression in tissue samples. CD79a is a highly specific B-cell lineage marker that plays an essential role in identifying and classifying B-lymphocytes in normal and malignant conditions.

This test is widely used in pathology and hematology to diagnose B-cell lymphomas and leukemias, and it is considered one of the most reliable markers for confirming B-cell origin in tumor cells. CD79a is expressed throughout most stages of B-cell development, making it a valuable diagnostic tool in immunophenotyping panels.

Benefits of the Test

• Confirms B-cell lineage in lymphoid tissues
• Helps diagnose B-cell lymphomas and leukemias
• Improves accuracy in tumor classification
• Differentiates B-cell tumors from T-cell malignancies
• Supports comprehensive hematopathology evaluation

Why Doctors Recommend This Test

Doctors recommend the IHC CD79a test when there is suspicion of B-cell-related blood cancers or lymphoid disorders. It is commonly used in:

• Evaluation of lymph node enlargement
• Suspected non-Hodgkin lymphoma cases
• Bone marrow biopsy analysis
• Leukemia classification
• Confirmation of B-cell origin in poorly differentiated tumors

CD79a is often used alongside markers such as CD20, PAX5, CD3, and CD45 to ensure accurate diagnosis and classification of lymphoid malignancies.

Preparation Before Test

No special preparation is required for the patient. Key points include:

• The test is performed on biopsy or bone marrow tissue samples
• No fasting or medication restrictions are needed
• Clinical history and previous pathology reports are important for interpretation

Normal Reporting Time

The test usually takes 3 to 5 working days, depending on laboratory processing time and sample complexity.

Who Should Take This Test

• Patients with suspected B-cell lymphoma
• Individuals with persistent lymph node enlargement
• Abnormal blood counts suggesting leukemia
• Bone marrow evaluation cases
• Patients undergoing cancer diagnosis or staging

The IHC CD79a test plays a crucial role in modern hematopathology by accurately identifying B-cell lineage in tissue samples. It helps pathologists distinguish between different types of lymphomas and leukemias, ensuring precise diagnosis and appropriate treatment planning.